Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 8/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13698420 | 0.80 | ALDH1A1 (0.57) | KMT2AMEN1ALDH1A1SMN1; SMN2USP2 | |
| SCHEMBL13698417 | 0.80 | KMT2A (0.57) | KMT2AMEN1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL17669252 | 0.79 | MAPT (0.71) | KMT2AMEN1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL15801114 | 0.79 | MAPT (0.71) | KMT2AMEN1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL13698426 | 0.77 | ALDH1A1 (0.54) | KMT2AMEN1ALDH1A1SMN1; SMN2USP2 | |
| SCHEMBL13698453 | 0.77 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2USP2 | |
| SCHEMBL3968371 | 0.75 | KMT2A (0.74) | KMT2AMEN1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL13698424 | 0.74 | MEN1 (0.56) | KMT2AMEN1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL3453846 | 0.74 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2USP2HSD11B1TSHR | |
| SCHEMBL336009 | 0.73 | NPC1 (0.65) | KMT2AMEN1ALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239873-A1 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | BLANCO MIGUEL GARCIA-GUZMAN | 2009-09-24 | — | — | US | disclosed |
| US-20090239873-A1 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | BLANCO MIGUEL GARCIA-GUZMAN | 2009-09-24 | — | — | US | disclosed |
| US-7563795-B2 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563795-B2 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239873-A1 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | KMT2A 1668/4885MEN1 3939/4885ALDH1A1 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.